1241833-16-8

Basic information

• Product Name: benzyl 2-(benzyloxy)-4-((4-cyclohexylbenzyl)amino)benzoate
• Synonyms: benzyl 2-(benzyloxy)-4-((4-cyclohexylbenzyl)amino)benzoate
• CAS NO: 1241833-16-8
• Molecular Weight: 505.657
• Mol File: 1241833-16-8.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: benzyl 2-(benzyloxy)-4-((4-cyclohexylbenzyl)amino)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: benzyl 2-(benzyloxy)-4-((4-cyclohexylbenzyl)amino)benzoate(1241833-16-8)
• EPA Substance Registry System: benzyl 2-(benzyloxy)-4-((4-cyclohexylbenzyl)amino)benzoate(1241833-16-8)

Safety Data

• Hazardous Substances Data: 1241833-16-8(Hazardous Substances Data)

Upstream product

• 25109-28-8 4-bromo(cyclohexyl)benzene 
• 27634-89-5 4-cyclohexylbenzaldehyde 
• 1241832-99-4 benzyl 4-amino-2-(benzyloxy)benzoate 
• 65-49-6 4-Aminosalicylic acid 
• 100-39-0 benzyl bromide 

Downstream Products

• 1334493-26-3 benzyl 2-(benzyloxy)-4-(N-(4-cyclohexylbenzyl)-2-(N-methylbiphenyl-4-ylsulfonamido)acetamido)benzoate 
• 1334493-29-6 benzyl 2-(benzyloxy)-4-(2-(4-chloro-N-methylphenylsulfonamido)-N-(4-cyclohexylbenzyl)acetamido)benzoate 
• 1334493-30-9 benzyl 2-(benzyloxy)-4-(N-(4-cyclohexylbenzyl)-2-(N-methylnaphthalene-1-sulfonamido)acetamido)benzoate 
• 1334493-33-2 benzyl 2-(benzyloxy)-4-(N-(4-cyclohexylbenzyl)-2-(N-methylquinoline-8-sulfonamido)acetamido)benzoate 
• 1334493-35-4 benzyl 2-(benzyloxy)-4-(N-(4-cyclohexylbenzyl)-2-(5-(dimethylamino)-N-methylnaphthalene-1-sulfonamido)acetamido)benzoate 
• 1334493-36-5 benzyl 2-(benzyloxy)-4-(N-(4-cyclohexylbenzyl)-2-(N,1-dimethyl-1H-imidazole-4-sulfonamido)acetamido)benzoate 
• 1334493-37-6 benzyl 2-(benzyloxy)-4-(2-(4-cyano-N-methylphenylsulfonamido)-N-(4-cyclohexylbenzyl)acetamido)benzoate 
• 1334493-38-7 benzyl 2-(benzyloxy)-4-(2-(4-bromo-N-methylphenylsulfonamido)-N-(4-cyclohexylbenzyl)acetamido)benzoate 
• 1334493-41-2 benzyl 2-(benzyloxy)-4-(2-(4-chloro-N-methylphenylsulfonamido)-N-(4-cyclohexylbenzyl)acetamido)benzoate 
• 1334493-44-5 benzyl 2-(benzyloxy)-4-(N-(4-cyclohexylbenzyl)-2-(4-fluoro-N-methylphenylsulfonamido)acetamido)benzoate 
• 1334493-45-6 benzyl 2-(benzyloxy)-4-(N-(4-cyclohexylbenzyl)-2-(4-methoxy-N-methylphenylsulfonamido)acetamido)benzoate 
• 1334493-46-7 benzyl 2-(benzyloxy)-4-(N-(4-cyclohexylbenzyl)-2-(N-methyl-4-nitrophenylsulfonamido)acetamido)benzoate 
• 1334493-48-9 benzyl 2-(benzyloxy)-4-(N-(4-cyclohexylbenzyl)-2-(2,3,4,5,6-pentafluoro-N-methylphenylsulfonamido)acetamido)benzoate 
• 1334492-84-0 4-(N-(4-cyclohexylbenzyl)-2-(N,3-dimethylphenylsulfonamido)acetamido)-2-hydroxybenzoic acid 

Relevant articles and documents

Design, synthesis, and in?vitro evaluation of BP-1-102 analogs with modified hydrophobic fragments for STAT3 inhibition

Twelve novel analogs of STAT3 inhibitor BP-1-102 were designed and synthesised with the aim to modify hydrophobic fragments of the molecules that are important for interaction with the STAT3 SH2 domain. The cytotoxic activity of the reference and novel co

Identification of bidentate salicylic acid inhibitors of PTP1B

PTP1B is a master regulator in the insulin and leptin metabolic pathways. Hyper-activated PTP1B results in insulin resistance and is viewed as a key factor in the onset of type II diabetes and obesity. Moreover, inhibition of PTP1B expression in cancer cells dramatically inhibits cell growth in vitro and in vivo. Herein, we report the computationally guided optimization of a salicylic acid-based PTP1B inhibitor 6, identifying new and more potent bidentate PTP1B inhibitors, such as 20h, which exhibited a > 4-fold improvement in activity. In CHO-IR cells, 20f, 20h, and 20j suppressed PTP1B activity and restored insulin receptor phosphorylation levels. Notably, 20f, which displayed a 5-fold selectivity for PTP1B over the closely related PTPσ protein, showed no inhibition of PTP-LAR, PRL2 A/S, MKPX, or papain. Finally, 20i and 20j displayed nanomolar inhibition of PTPσ, representing interesting lead compounds for further investigation.

NEW SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF

The present invention relates to novel compounds, compositions containing same and methods for inhibiting STAT3 and/or STAT5 activity or for the treatment of a STAT3 or STAT5-dependent cancer using said compounds; or a pharmaceutically acceptable salt, solvate or prodrug thereof.